Contraception
RSSArticles
-
Contraception: More Effective Than Ever?
A new analysis from the National Survey of Family Growth demonstrates a decrease from 12% in 2002 to 10% in 2006-2010 in the overall rate of failure among women using reversible methods of contraception.
-
Contraception, Migraines, and Stroke
In this case-control study, women with migraines with aura using combined hormonal contraception had six times the odds of experiencing ischemic stroke compared to women without migraines not using combined hormonal contraception. Use of combined hormonal contraception among women with migraines without aura was not associated with an increased risk of stroke over baseline.
-
Reproductive Rights in 2017: Standing Strong for Women
The evidence strongly suggests that comprehensive family planning services provided under the Affordable Care Act that include subsidized coverage for highly effective long-acting reversible contraception have contributed to a decrease in the rate of unintended pregnancy and a sharp decline in abortions. As women’s healthcare providers, we should be leaders in standing up to policy changes that will endanger women and threaten our most vulnerable citizens.
-
Hormonal Contraception: A Risk Factor for Depression?
A population-based study suggests that hormonal contraception increases the risk of treatment for depression, but bias provides a more likely explanation for the association.
-
PCOS and Hormonal Contraception: A Tale of Two Syndromes?
Emerging evidence supports that two metabolic phenotypes exist among women with PCOS. For metabolically healthy PCOS patients, managing menstrual symptoms, anovulation and androgen excess with COCs provides a simple and well-tolerated treatment regimen. In contrast, PCOS patients with metabolic syndrome are at high risk for type 2 diabetes, and COC use may contribute to hyperinsulinemia, adverse lipid changes, and endothelial changes associated with adverse cardiovascular risk. The use of a levonorgestrel intrauterine device combined with spironolactone (to manage hyperandrogenism) and metformin (to manage hyperinsulinism) may offer advantages to metabolically unhealthy PCOS patients.
-
Is an Even Safer Combined Oral Contraceptive Pill Available?
ABSTRACT & COMMENTARY: New study has many advantages, including ascertainment of important confounding variables.
-
Still Highly Effective: LNG IUS 52 mg at 7 Years
Data from a large randomized study conducted by the World Health Organization demonstrate that pregnancy rates do not increase after year five, and support the continued use of the levonorgestrel intrauterine system 52 mg for contraception through seven years.
-
Immediate Postpartum IUD Insertion: Ready for Prime Time?
It is no secret that long-acting reversible contraception, such as intrauterine devices and implants, are among the most effective methods.
-
When Do Combined Oral Contraceptives Start Working After Ulipristal Acetate Emergency Contraception?
In this randomized, controlled trial of the effects of combined oral contraceptives on ovarian activity after taking ulipristal acetate, investigators found that some women needed up to 14 days to achieve ovarian quiescence. Therefore, abstinence or backup contraception should be used during that time.
-
Liletta: A New LNG-IUS Option
Initial clinical results with a new 52 mg levonorgestrel intrauterine system recently introduced to the market and approved for three years of use are similar to those seen with the existing system.